Size: | Price | Quantity | |
---|---|---|---|
1 mg | $50.00 | ||
5 mg | $120.00 |
Lestaurtinib (111358-88-4) is a potent and selective FLT3 inhibitor (IC50= 2 nM).1,2 Inhibits RET and RET phosphorylation in medullary thyroid carcinoma cells.3 Suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.4 Potent Trk inhibitor.5 Cell permeable.
References/Citations:
1) Levis et al. (2003), Novel FLT3 tyrosine kinase inhibitors; Expert Opin. Investig. Drugs, 12 1951
2) Chen et al. (2005), FLT3/ITD Mutation Signaling Includes Suppression of SHP-1; J. Biol. Chem., 280 5361
3) Strock et al. (2003), CEP-701 and CEP-751 Inhibit Constitutively Activated RET Tyrosine Kinase Activity and Block Medullary Thyroid Carcinoma Cell Growth; Cancer Res., 63 5559
4) Hexner et al. (2008), Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders; Blood, 111 5663
5) Ruggeri et al. (1999), Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models; Curr. Med. Chem., 6 845
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Lestaurtinib (111358-88-4) is a potent and selective FLT3 inhibitor (IC50= 2 nM).1,2 Inhibits RET and RET phosphorylation in medullary thyroid carcinoma cells.3 Suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.4 Potent Trk inhibitor.5 Cell permeable.
References/Citations:
1) Levis et al. (2003), Novel FLT3 tyrosine kinase inhibitors; Expert Opin. Investig. Drugs, 12 1951
2) Chen et al. (2005), FLT3/ITD Mutation Signaling Includes Suppression of SHP-1; J. Biol. Chem., 280 5361
3) Strock et al. (2003), CEP-701 and CEP-751 Inhibit Constitutively Activated RET Tyrosine Kinase Activity and Block Medullary Thyroid Carcinoma Cell Growth; Cancer Res., 63 5559
4) Hexner et al. (2008), Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders; Blood, 111 5663
5) Ruggeri et al. (1999), Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models; Curr. Med. Chem., 6 845
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.